Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors

G. Mantovani, D. Treppiedi, E. Giardino, R. Catalano, F. Mangili, P. Vercesi, M. Arosio, A. Spada, E. Peverelli

Research output: Contribution to journalReview articlepeer-review


Although generally benign, pituitary tumors are frequently locally invasive, with reduced success of neurosurgery and unresponsive to pharmacological treatment with somatostatin or dopamine analogues. The molecular basis of the different biological behavior of pituitary tumors are still poorly identified, but a body of work now suggests that the activity of specific cytoskeleton proteins is a key factor regulating both the invasiveness and drug resistance of these tumors. This review recapitulates the experimental evidence supporting a role for the actin-binding protein filamin A (FLNA) in the regulation of somatostatin and dopamine receptors expression and signaling in pituitary tumors, thus in determining the responsiveness to currently used drugs, somatostatin analogues and dopamine receptor type 2 agonists. Regarding the regulation of invasive behavior of pituitary tumoral cells, we bring evidence to the role of the actin-severing protein cofilin, whose activation status may be modulated by dopaminergic and somatostatinergic drugs, through FLNA involvement. Molecular mechanisms involved in the regulation of FLNA expression and function in pituitary tumors will also be discussed.

Original languageEnglish
Pages (from-to)R95-R108
JournalEndocrine-Related Cancer
Issue number2
Publication statusPublished - Feb 1 2019


  • Cofilin
  • Dopamine receptor type 2
  • Filamin A
  • Pituitary tumors
  • Somatostatin receptor 2

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research


Dive into the research topics of 'Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors'. Together they form a unique fingerprint.

Cite this